ELEV Elevation Oncology
- 3.540
- +0.260+7.93%
Elevation Oncology News
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
Wedbush: Reiterates Elevation Oncology (ELEV.US) rating and adjusted from superior to superior market rating, target price of $8.00.
Wedbush: Reiterates Elevation Oncology (ELEV.US) rating and adjusted from superior to superior market rating, target price of $8.00.
Wedbush Reiterates Outperform on Elevation Oncology, Maintains $8 Price Target
Wedbush analyst Robert Driscoll reiterates Elevation Oncology (NASDAQ:ELEV) with a Outperform and maintains $8 price target.
Analysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA)
Wedbush Sticks to Its Buy Rating for Elevation Oncology (ELEV)
Elevation Oncology: A Promising Future With HER3-ADC Candidate Amidst Financial Stability
Elevation Oncology Shares Swing to 5% Gain After Extending Cash Runway
By Chris Wack Elevation Oncology shares rose after the company said it has raised enough cash though a stock facility that it has extended its cash runway into 2026. Shares were up 5% to $4.14 in re
Elevation Oncology Files for $350M Mixed Shelf
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out
Elevation Oncology Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results.
Elevation Oncology Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results.
Elevation Oncology Says Cash, Cash Equivalents And Marketable Securities Of $104.1M As Of March 31, 2024, Plus $14.5M In Net Proceeds Raised Under Its ATM Facility Subsequent To Q1 Of 2024, To Be Sufficient To Fund Its Current Operations Into 2026
Elevation Oncology Says Cash, Cash Equivalents And Marketable Securities Of $104.1M As Of March 31, 2024, Plus $14.5M In Net Proceeds Raised Under Its ATM Facility Subsequent To Q1 Of 2024, To Be Suff
Elevation Oncology Q1 2024 GAAP EPS $(0.23) Misses $(0.20) Estimate
Elevation Oncology (NASDAQ:ELEV) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.20) by 15 percent. This is a 68.06 percent increase over losses of $(
Elevation Oncology Raised $44.2 M Yr-to-date Through ATM Facility, Extending Cash Runway Into 2026 >ELEV
Elevation Oncology Raised $44.2 M Yr-to-date Through ATM Facility, Extending Cash Runway Into 2026 >ELEV
Press Release: Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements PR Newswire BOSTON, May 2, 2024 -- Enrollment ongoing in Phase 1 clinical trial of EO-302
Elevation Oncology 1Q Loss/Shr 23c >ELEV
Elevation Oncology 1Q Loss/Shr 23c >ELEV
Promising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation Oncology
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
Lori Hu Resigns, Darcy Mootz Joins Elevation Oncology Board
Elevation Oncology (ELEV) has shared an announcement.
Watching Elevation Oncology; Traders Circulate M&A Blog Comments Saying 'The Intensity Of M&A Interest Among ADC Developers As Well As A Transactional ELEV Management Team Have Made This Company Hard To Ignore'
Watching Elevation Oncology; Traders Circulate M&A Blog Comments Saying 'The Intensity Of M&A Interest Among ADC Developers As Well As A Transactional ELEV Management Team Have Made This Company Hard
Analysis
Price Target
No Data
